Monoclonal antibody: a cell specific immunotherapy to treat cancer

Authors

  • M. Ashikur Rahman Department of Pharmacy, Primeasia University, Banani, Dhaka, Bangladesh
  • Fargana Islam Department of Pharmacy, Primeasia University, Banani, Dhaka, Bangladesh
  • Mahedi Hasan Department of Pharmacy, Primeasia University, Banani, Dhaka, Bangladesh
  • Irin S. Joya Department of Pharmacy, Primeasia University, Banani, Dhaka, Bangladesh
  • Maisha M. Mithila Department of Pharmacy, Primeasia University, Banani, Dhaka, Bangladesh
  • M. Fahim Islam Department of Pharmacy, Primeasia University, Banani, Dhaka, Bangladesh
  • M. Rashedur Rahman Department of Pharmacy, Primeasia University, Banani, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20230404

Keywords:

Monoclonal antibody, Combined chemotherapy, Antibody-drug conjugates, Immunotherapy, Cancer

Abstract

Fundamentally, the therapy technique which is utilized in malignancy immunotherapy, monoclonal antibodies (mAb), is one of them, and it is used extensively as a treatment for the disease. To achieve more successful treatment, novel combination treatments and treatment procedures must be created. The purpose of this study is the improvement of mAb treatment and detail late advance and new limits, particularly in cancer therapy. With various keywords, we searched Google Scholar, PubMed, and Scopus for monoclonal antibody therapy as an alternate form of chemotherapy. The number of patients who received each therapy regimen, and the recovery rate are all displayed in this study, also a comparative study between monotherapy and chemotherapy. The result showed that rituximab had a greater overall response rate than other drugs, at 68%. In the combination treatment group (monotherapy+chemotherapy), 100% of patients had adverse events, compared to 84.2 percent in the monotherapy group. The pharmaceutical industry's fastest-growing medications, monoclonal antibodies are increasingly being examined in Clinical trials as stand-alone treatments or in conjunction with other therapies. It has a promising future since it will provide better tailored therapy and combination therapy for the treatment of cancer.

References

Gray, Juliet C, Sondel PM. ‘Overview of Monoclonal Antibody Therapies’. Immunotherapy Pediatric Malignancies. 2017;65-78.

Weiner LM, Surana R, Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317-27.

Rogers LM, Veeramani S, Weiner GJ. Complement in monoclonal antibody therapy of cancer. Immunol Res. 2014;59(1-3):203-10.

Kimiz-Gebologlu I, Gulce-Iz S, Biray-Avci C. Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep. 2018;45(6):2935-40.

Pento JT. Monoclonal antibodies for the treatment of cancer. Anticanc Res. 2017;37(11):5935-9.

Banker DD. Monoclonal antibodies. A review. Indian J Med Sci. 2001;55(12):651-4.

Coulson A, Levy A, Gossell-Williams M. Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations. West Indian Med J. 2014;63(6):650-4.

Pierpont TM, Limper CB, Richards KL. Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. Front Oncol. 2018;8:163.

Grilo AL, Mantalaris A. The Increasingly Human and Profitable Monoclonal Antibody Market. Trends Biotechnol. 2019;37(1):9-16.

Zhang C. Hybridoma technology for the generation of monoclonal antibodies. Methods Mol Biol. 2012;901:117-35.

Moraes JZ, Hamaguchi B, Braggion C, Speciale ER, Cesar FBV, Soares GFDS, Osaki JH, Pereira TM, Aguiar RB. Hybridoma technology: is it still useful? Curr Res Immunol. 2021;2:32-40.

Mitra S, Tomar PC. Hybridoma technology; advancements, clinical significance, and future aspects. J Genet Eng Biotechnol. 2021;19(1):159.

Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res. 2007;39(1-3):271-8.

Hendriks D, Choi G, de Bruyn M, Wiersma VR, Bremer E. Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches. Int Rev Cell Mol Biol. 2017;331:289-383.

Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol. 2012;22(1):3-13.

Ning YM, Suzman D, Maher VE. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy. Oncologist. 2017;22(6):743-9.

Walker JW, Lebbé C, Grignani G, Nathan P, Dirix L, Fenig E, et al. Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. J Immunother Cancer. 2020;8(1):e000313.

Xu R, Xu C, Liu C, Cui C, Zhu J. Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer. Onco Targets Ther. 2018;11:8605-21.

Baggi A, Quaglino P, Rubatto M, Depenni R, Guida M, Ascierto PA, et al. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Eur J Cancer. 2021;157:250-8.

Mitani S, Tanaka K, Suzuki S, Kanemura H, Haratani K, et al. Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study. Anticancer Drugs. 2021;32(1):95-101.

Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, et al. Clinical efficacy of Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37-44.

Ploessl C, Pan A, Maples KT, Lowe DK. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma. Ann Pharmacother. 2016;50(5):416-22.

Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016;34(26):3119-25.

Jamil F, Shafqat M, Samuel S, Shah Z, Durer C, Durer S, et al. Efficacy and Toxicity Profile of Elotuzumab for Multiple Myeloma: A Systematic Review and Meta-Analysis. Blood. 2018;132(1):5640.

Yamazaki N, Kiyohara Y, Uhara H, Tsuchida T, Maruyama K, Shakunaga N, Itakura E, Komoto A. Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance. J Dermatol. 2020;47(8):834-48.

Martin T, Strickland S, Glenn M, Charpentier E, Guillemin H, Hsu K, Mikhael J. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer J. 2019;9:41.

Broderick JM. Mogamulizumab Receives FDA Approval for CTCL. 2018. Available at: https://www.onclive.com/view/fda-approves-mogamulizumab-for-ctcl. Accessed on 12 November 2022.

Inman S. FDA Approves Necitumumab for Squamous NSCLC. 2015. Available at: https://www.onclive. com/view/fda-approves-necitumumab-for-squamous-nsclc. Accessed on 12 November 2022.

Lawrence L. FDA Approves Second PD-1 Inhibitor, Nivolumab, for Melanoma. 2014. Available at: https://www.cancernetwork.com/view/fda-approves-second-pd-1-inhibitor-nivolumab-melanoma. Accessed on 12 November 2022.

Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, et al. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. 2016;21(5):634-42.

Indications and Year of First Approval for Each Antibody Were Accessed Using the FDA Drug Database. Available at: https://www.accessdata. fda.gov/scripts/cder/daf/. Accessed on 12 November 2022.

Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, et al. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol. 2015;33(30):3467-74.

Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, et al. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica. 2015;100(4):511-6.

Columbus G. Olaratumab Combination Misses OS Endpoint for Sarcoma in Phase III Trial. 2019. Available at: https://www.targetedonc.com/view/ olaratumab-combination-misses-os-endpoint-for-sarcoma-in-phase-iii-trial. Accessed on 12 November 2022.

Chen Q, Cheng M, Wang Z, Zhao S. The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis. Medicine (Baltimore). 2016;95(50):e5284.

FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. 2017. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication. Accessed on 12 November 2022.

Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart MJ. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273-82.

Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, et al. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. Target Oncol. 2018;13(2):227-34.

Kudo M. Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma. Liver Cancer. 2018;7:305-11.

Dotan E, Aggarwal C, Smith MR. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. 2010;35(3):148-57.

Li H, Shao B, Yan Y, Song G, Liu X, Wang J, Liang X. Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer. Chin J Cancer Res. 2016;28(3):330-8.

Dima D, Dower J, Comenzo RL, Varga C. Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy. Cancer Manag Res. 2020;12:7891-903.

Park K, Cho EK, Bello M, Ahn MJ, Thongprasert S, Song EK, Soldatenkova V, Depenbrock H, Puri T, Orlando M. Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study. Cancer Res Treat. 2017;49(4):937-46.

Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, Pruitt SK, Leary A. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019;37(17):1470-8.

Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, et al. Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749-55.

Luo C, Wu G, Huang X, Ma Y, Zhang Y, Song Q, et al. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis. Sci Rep. 2021;11(1):3255.

Isono T, Kagiyama N, Shibata S, Nakajima H, Matsui Y, Takano K, et al. A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non-small cell lung cancer. Thorac Cancer. 2021;12(9):1387-97.

Downloads

Published

2023-02-22

How to Cite

Rahman, M. A., Islam, F., Hasan, M., Joya, I. S., Mithila, M. M., Islam, M. F., & Rahman, M. R. (2023). Monoclonal antibody: a cell specific immunotherapy to treat cancer. International Journal of Basic & Clinical Pharmacology, 12(2), 290–302. https://doi.org/10.18203/2319-2003.ijbcp20230404

Issue

Section

Review Articles